Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.
Piesche M, Roos J, Kühn B, Fettel J, Hellmuth N, Brat C, Maucher IV, Awad O, Matrone C, Comerma Steffensen SG, Manolikakes G, Heinicke U, Zacharowski KD, Steinhilber D, Maier TJ. Piesche M, et al. Among authors: maucher iv. Front Pharmacol. 2020 Sep 3;11:1297. doi: 10.3389/fphar.2020.01297. eCollection 2020. Front Pharmacol. 2020. PMID: 33013366 Free PMC article. Review.
Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418.
Maucher IV, Rühl M, Kretschmer SB, Hofmann B, Kühn B, Fettel J, Vogel A, Flügel KT, Manolikakes G, Hellmuth N, Häfner AK, Golghalyani V, Ball AK, Piesche M, Matrone C, Geisslinger G, Parnham MJ, Karas M, Steinhilber D, Roos J, Maier TJ. Maucher IV, et al. Biochem Pharmacol. 2017 Feb 1;125:55-74. doi: 10.1016/j.bcp.2016.11.004. Epub 2016 Nov 4. Biochem Pharmacol. 2017. PMID: 27823964
Anti-inflammatory nitro-fatty acids suppress tumor growth by triggering mitochondrial dysfunction and activation of the intrinsic apoptotic pathway in colorectal cancer cells.
Kühn B, Brat C, Fettel J, Hellmuth N, Maucher IV, Bulut U, Hock KJ, Grimmer J, Manolikakes G, Rühl M, Kühn A, Zacharowski K, Matrone C, Urbschat A, Roos J, Steinhilber D, Maier TJ. Kühn B, et al. Among authors: maucher iv. Biochem Pharmacol. 2018 Sep;155:48-60. doi: 10.1016/j.bcp.2018.06.014. Epub 2018 Jun 15. Biochem Pharmacol. 2018. PMID: 29909078
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Roos J, Peters M, Maucher IV, Kühn B, Fettel J, Hellmuth N, Brat C, Sommer B, Urbschat A, Piesche M, Vogel A, Proschak E, Blöcher R, Buscató E, Häfner AK, Matrone C, Werz O, Heidler J, Wittig I, Angioni C, Geisslinger G, Parnham MJ, Zacharowski K, Steinhilber D, Maier TJ. Roos J, et al. Among authors: maucher iv. Antioxid Redox Signal. 2018 May 10;28(14):1265-1285. doi: 10.1089/ars.2017.7155. Epub 2017 Sep 8. Antioxid Redox Signal. 2018. PMID: 28699354
Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Roos J, Grösch S, Werz O, Schröder P, Ziegler S, Fulda S, Paulus P, Urbschat A, Kühn B, Maucher I, Fettel J, Vorup-Jensen T, Piesche M, Matrone C, Steinhilber D, Parnham MJ, Maier TJ. Roos J, et al. Pharmacol Ther. 2016 Jan;157:43-64. doi: 10.1016/j.pharmthera.2015.11.001. Epub 2015 Nov 6. Pharmacol Ther. 2016. PMID: 26549540 Review.
Characterization of the molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles.
Kretschmer SB, Woltersdorf S, Vogt D, Lillich FF, Rühl M, Karas M, Maucher IV, Roos J, Häfner AK, Kaiser A, Wurglics M, Schubert-Zsilavecz M, Angioni C, Geisslinger G, Stark H, Steinhilber D, Hofmann B. Kretschmer SB, et al. Among authors: maucher iv. Biochem Pharmacol. 2017 Jan 1;123:52-62. doi: 10.1016/j.bcp.2016.09.021. Epub 2016 Sep 23. Biochem Pharmacol. 2017. PMID: 27671344